CASEIN KINASE 1 INHIBITORS FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F16%3A00088788" target="_blank" >RIV/00216224:14740/16:00088788 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20161214&DB=&locale=&CC=EP&NR=2882437B1&KC=B1&ND=1#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20161214&DB=&locale=&CC=EP&NR=2882437B1&KC=B1&ND=1#</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
CASEIN KINASE 1 INHIBITORS FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
Original language description
The invention relates to inhibitors of casein kinase 1 for use in the treatment of B-cell chronic lymphocytic leukemia.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
EP2882437 (B1)
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Dec 14, 2016
Owner name
MASARYKOVA UNIVERZITA
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence